PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UCB announces approval of Bimzelx

The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis.

UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Bimzelx, also known as bimekizumab.

The therapy is used for the treatment of adult patients with active psoriatic arthritis (PsA) and adult patients with active axial spondyloarthritis (axSpA).

Bimzelx is the first approved treatment for PsA and axSpA that has been developed to inhibit IL-17A and IL-17F – two key cytokines driving the inflammatory process.

The MHRA has approved bimekizumab alone or in combination with methotrexate for the treatment of adults with active PsA who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.

In active axSpA, the MHRA has approved bimekizumab for the treatment of adults with active nr-axSpA with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs.

Across the PsA studies, bimekizumab showed improvements compared to placebo in joint and skin symptoms across biologic-naïve and TNF inhibitor-inadequate responder populations. In the axSpA studies, the drug demonstrated improvements compared to placebo in signs, symptoms and disease activity across the spectrum of the condition.

Claire Brading, managing director UK and Ireland at UCB, reflected: “The approval of Bimzelx in psoriatic arthritis and axial spondyloarthritis is a significant milestone for the rheumatology community in the UK. At UCB we are committed to exploring innovative solutions that enable patients to maintain disease control and live their lives as free as possible from the burden of their condition.”

She concluded: “We are extremely proud to be able to bring a new dual action biological treatment option to a broad range of people living with psoriatic arthritis and axial spondyloarthritis in the UK.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026